B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

ABSTRACT: Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there is no cure for MM, patients eventually become resistant to therapies, leading to development of relapsed/refractory MM. Therefore, an unmet need exists for MM treatments with novel mechanisms of action that can provide durable responses, evade resistance to prior therapies, and/or are better tolerated. B-cell maturation antigen (BCMA) is preferentially expressed by mature B lymphocytes, and its overexpression and activation are associated with MM in preclinical models and human

SUBMITTER: Shah N 

PROVIDER: S-EPMC7214244 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature